### NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# **Technology Appraisal Review**

Part review of TA139; Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (recommendation 1.2)

### Stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company(ies)	General
DeVilbiss Healthcare	All Wales Therapeutics and Toxicology
Reswell	Centre
Hoffrichter	Allied Health Professionals Federation
ResMed	<ul> <li>Board of Community Health Councils in Wales</li> </ul>
Patient/carer groups	British National Formulary
Black Health Agency	Care Quality Commission
British Lung Foundation	Chest, Heart and Stroke Scotland
British Snoring and Sleep Apnoea	Department of Health, Social Services
Association	and Public Safety for Northern Ireland
Hope2Sleep	EUCOMED
Muslim Council of Britain	Healthcare Improvement Scotland
Narcolepsy UK	Medicines and Healthcare products
Neurological Alliance	Regulatory Agency
OSA Partnership Group	<ul> <li>National Association of Primary Care</li> </ul>
Sleep Apnoea Trust	<ul> <li>National Pharmacy Association</li> </ul>
South Asian Health Foundation	<ul> <li>Neurological Alliance of Scotland</li> </ul>
Specialised Healthcare Alliance	NHS Alliance
The Brain Charity	NHS Confederation
The Sleep Council	NHS Supply Chain
•	Northern Ireland Chest, Heart and
Professional groups	Stroke Association
Association for Respiratory	<ul> <li>Scottish Medicines Consortium</li> </ul>
Technology & Physiology	Wales Neurological Alliance
<ul> <li>Association of British Neurologists</li> </ul>	Welsh Health Specialised Services
<ul> <li>Association of Respiratory Nurse Specialists</li> </ul>	Committee
British Association of Neuroscience	Possible comparator company(ies)
Nurses	None
British Geriatrics Society	
British Neuropathological Society	Relevant research groups
British Neuropsychiatry Association	Brain Research UK
British Sleep society	British Association for Lung Research
British Society of Dental Sleep	British Neurological Research Trust
Medicine	Cochrane Airways Group
British Thoracic Society	Cochrane Common Mental Disorders
Institute of Neurology	Group

TA139; Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome. Issue date: October 2019

Consultees	Commentators (no right to submit or appeal)
<ul> <li>National Heart and Lung Institute</li> <li>Primary Care and Community Neurology Society Primary Care</li> <li>Respiratory Society UK</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine – Sleep medicine section</li> <li>UK Clinical Pharmacy Association</li> </ul>	<ul> <li>Genomics England</li> <li>MRC Clinical Trials Unit</li> <li>National Hospital for Neurology and Neurosurgery</li> <li>National Institute for Health Research</li> <li>Oxford sleep unit, Oxford Centre for Respiratory Medicine</li> <li>Sleep Research Group, Section of Psychological Medicine, University of Glasgow</li> </ul>
Others  Department of Health and Social Care  NHS Airedale, Wharfedale and Craven CCG  NHS England	<ul> <li>Associated Public Health Groups</li> <li>Public Health England</li> <li>Public Health Wales</li> </ul>
<ul><li>NHS South Cheshire CCG</li><li>Welsh Government</li></ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### **Definitions:**

### **Consultees**

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

## **Commentators**

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary.

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.